Leading orphan drugs based on R&D phase III cost 2015

The data shows the research and development phase III cost of the top 10 drugs based on net present value, as of 2015. Actelion's Uptravi had a total R&D phase III cost of 185 million USD. Orphan drugs are used to target rare diseases or disorders, which in the U.S. is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the U.S. through the Orphan Drug Act of 1983.